PL3988656T3 - Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu - Google Patents

Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Info

Publication number
PL3988656T3
PL3988656T3 PL21193940.0T PL21193940T PL3988656T3 PL 3988656 T3 PL3988656 T3 PL 3988656T3 PL 21193940 T PL21193940 T PL 21193940T PL 3988656 T3 PL3988656 T3 PL 3988656T3
Authority
PL
Poland
Prior art keywords
nucleosome
protein domains
genome modification
targeted genome
acting protein
Prior art date
Application number
PL21193940.0T
Other languages
English (en)
Inventor
Fuqiang Chen
Xiao DING
Yongmei FENG
Gregory D Davis
Original Assignee
Sigma-Aldrich Co. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Aldrich Co. Llc filed Critical Sigma-Aldrich Co. Llc
Publication of PL3988656T3 publication Critical patent/PL3988656T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL21193940.0T 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu PL3988656T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
PL3988656T3 true PL3988656T3 (pl) 2024-12-16

Family

ID=62916578

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18182999T PL3428274T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu
PL21193940.0T PL3988656T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18182999T PL3428274T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Country Status (17)

Country Link
US (3) US10604752B2 (pl)
EP (2) EP3988656B9 (pl)
JP (3) JP6994560B2 (pl)
KR (3) KR102655021B1 (pl)
CN (1) CN111183226A (pl)
AU (3) AU2018299995B2 (pl)
CA (1) CA3066790C (pl)
DK (2) DK3988656T3 (pl)
ES (2) ES2997490T3 (pl)
FI (1) FI3988656T3 (pl)
GB (3) GB2567917B (pl)
IL (2) IL309801B2 (pl)
LT (2) LT3988656T (pl)
PL (2) PL3428274T3 (pl)
PT (2) PT3988656T (pl)
SG (1) SG11201911864PA (pl)
WO (1) WO2019014230A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
KR102655021B1 (ko) 2017-07-11 2024-04-04 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
WO2019161290A1 (en) * 2018-02-15 2019-08-22 Sigma-Aldrich Co. Llc Engineered cas9 systems for eukaryotic genome modification
AU2019255789B2 (en) 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
CA3102676A1 (en) 2018-06-04 2019-12-12 University Of Copenhagen Mutant cpf1 endonucleases
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
CN111718420B (zh) * 2019-03-19 2021-09-14 华东师范大学 一种用于基因治疗的融合蛋白及其应用
CN111718418B (zh) * 2019-03-19 2021-08-27 华东师范大学 一种增强基因编辑的融合蛋白及其应用
WO2020187272A1 (zh) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 一种用于基因治疗的融合蛋白及其应用
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
JP2022533589A (ja) * 2019-05-13 2022-07-25 イーエムディ・ミリポア・コーポレイション Ｃｒｉｓｐｒタンパク質をコードする合成自己複製ｒｎａベクターおよびその使用
CA3153563A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
JP7785002B2 (ja) 2019-11-05 2025-12-12 ペアーワイズ プランツ サービシズ， インコーポレイテッド 対立遺伝子のｒｎａにコードされたｄｎａの置換のための組成物および方法
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
US20230159927A1 (en) * 2020-05-08 2023-05-25 Duke University Chromatin remodelers to enhance targeted gene activation
KR102679001B1 (ko) * 2020-09-21 2024-06-28 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
US20230365992A1 (en) * 2020-09-21 2023-11-16 Korea University Research And Business Foundation Novel enhanced base editing or revising fusion protein and use thereof
KR102699756B1 (ko) * 2020-09-24 2024-08-29 고려대학교 산학협력단 편집 효율이 향상된 프라임 편집 기반 유전자 교정용 조성물 및 이의 용도
AU2021374974A1 (en) * 2020-11-06 2023-05-25 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN114507689B (zh) * 2022-01-27 2024-01-16 山东大学 一种提高真核生物基因编辑效率的方法及其应用
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用
CN115948465B (zh) * 2022-12-16 2025-09-19 中国农业科学院北京畜牧兽医研究所 猪hat1基因修饰系统及应用
WO2026097018A1 (en) * 2024-11-04 2026-05-07 Intellia Therapeutics, Inc. Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
WO2013152220A2 (en) * 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
CN116622704A (zh) * 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
US20140273230A1 (en) * 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
CN105408483A (zh) * 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2016036754A1 (en) * 2014-09-02 2016-03-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
EP3204496A1 (en) * 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
WO2016103233A2 (en) 2014-12-24 2016-06-30 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
EP3313445A1 (en) 2015-06-24 2018-05-02 Sigma Aldrich Co. LLC Cell cycle dependent genome regulation and modification
US11339408B2 (en) 2015-08-20 2022-05-24 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR102655021B1 (ko) 2017-07-11 2024-04-04 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용

Also Published As

Publication number Publication date
GB2598847A (en) 2022-03-16
EP3988656A1 (en) 2022-04-27
AU2022200851A1 (en) 2022-03-03
US12065642B2 (en) 2024-08-20
PL3428274T3 (pl) 2022-01-03
PT3988656T (pt) 2024-11-07
ES2901629T3 (es) 2022-03-23
KR20230053732A (ko) 2023-04-21
GB202114520D0 (en) 2021-11-24
AU2021245148B2 (en) 2024-01-04
FI3988656T3 (fi) 2024-10-29
EP3988656B9 (en) 2024-11-27
EP3988656B1 (en) 2024-09-18
GB2598847B (en) 2022-06-01
CN111183226A (zh) 2020-05-19
LT3428274T (lt) 2021-11-25
PT3428274T (pt) 2021-11-05
KR20200021529A (ko) 2020-02-28
US20200208135A1 (en) 2020-07-02
WO2019014230A1 (en) 2019-01-17
SG11201911864PA (en) 2020-01-30
LT3988656T (lt) 2024-11-11
DK3988656T3 (da) 2024-11-11
GB202103935D0 (en) 2021-05-05
IL309801A (en) 2024-02-01
US20210024916A1 (en) 2021-01-28
JP7469285B2 (ja) 2024-04-16
GB2593814A (en) 2021-10-06
IL309801B1 (en) 2024-08-01
IL271197B1 (en) 2024-02-01
JP6994560B2 (ja) 2022-02-21
JP2024096783A (ja) 2024-07-17
DK3428274T3 (da) 2021-11-15
KR20240046316A (ko) 2024-04-08
GB2567917B (en) 2021-05-12
AU2018299995A1 (en) 2020-01-02
AU2018299995B2 (en) 2021-10-28
JP2022046532A (ja) 2022-03-23
KR102523217B1 (ko) 2023-04-20
GB2567917A (en) 2019-05-01
GB201811358D0 (en) 2018-08-29
ES2997490T3 (en) 2025-02-17
BR112019028261A2 (pt) 2020-07-14
CA3066790C (en) 2023-07-18
IL309801B2 (en) 2024-12-01
EP3428274B1 (en) 2021-10-13
GB2593814B (en) 2022-01-05
IL271197B2 (en) 2024-06-01
US12221606B2 (en) 2025-02-11
JP2020530287A (ja) 2020-10-22
AU2021245148A1 (en) 2021-11-04
US20190017042A1 (en) 2019-01-17
JP7891501B2 (ja) 2026-07-16
CA3066790A1 (en) 2019-01-17
IL271197A (en) 2020-01-30
EP3428274A1 (en) 2019-01-16
AU2022200851B2 (en) 2023-12-14
KR102655021B1 (ko) 2024-04-04
US10604752B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
LT3988656T (lt) Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui
IL295358A (en) Using programmable dna binding proteins to enhance targeted genome modification
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL290809A (en) Tau-protein targeting protacs and associated methods of use
PL3961932T3 (pl) Wykrywanie problemów z intermodulacją i konfiguracja schematów transmisji w celu rozwiązania problemów z intermodulacją
EP3695666C0 (en) DETECTION OF DRIVING ACTIONS THAT MITIGATE RISK
LT3383916T (lt) Antikūnai prieš cd73 ir jų panaudojimo būdai
EP3781053C0 (en) ROBOTIC PORT PLACEMENT GUIDE
EP3737322A4 (en) GUIDANCE FOR THE PLACEMENT OF SURGICAL ORIFICES
IL269642A (en) Methods and compositions for enhancing health
IL256079A (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
IL269219A (en) Enzymatic production of hexoses
EP3503933C0 (en) USE OF TISSUE FOR INJURY REPAIR
EP3529229A4 (en) POLYMORPHIC FORMS OF SODIUM BENZOATE AND THEIR USES
PL3655013T3 (pl) Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii
IL271223A (en) Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
IL270817A (en) Use of glutamine synthetase for treating hyperammonemia
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
EP3171695C0 (en) USING VISUAL CUES TO IMPROVE BIRD-REPELLING COMPOSITIONS
LT3368044T (lt) Kepenų steatozės, susijusios su oligo-ovuliacija, gydymas
IL271164A (en) Use of vibegron to treat overactive bladder
PL3550972T3 (pl) Sposób leczenia w celu usunięcia ektopasożytów z ryb
IL263997A (en) Human-enzyme mediated depletion of cystine
EP3526321C0 (en) USE OF TONIC AGENTS TO INCREASE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUSES
LT3063287T (lt) Monensino naudojimas rekombinantinių baltymų glikozilinimui reguliuoti